Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.8MCash on Hand
4mo Cash Runway
Follow COSM by emailGet an email when COSM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about COSM, unsubscribe in one click. Privacy
📣 What COSM Says Is Next
Q4 2026 · “Revenue Analysis Expected Q4 2026 U.S. results Amount First orders from new subscribers ~$8.2 million Renewals of subscriptions started during the quarter ~$3.3 million Total subscription revenue ~$11.5 million One-time purchases ~$3.5 million Total U.S. revenue ~$15.0 million Subscriptions are expected to generate approximately $11.5 million, or more than three-quarters, of fourth quarter U.S. revenue.”
Company press release, Oct 22, 2026 · SEC filing
fourth quarter · “We are reaffirming our outlook to surpass $90 million in revenue this year, and we currently expect the fourth quarter to be the strongest in our history.” 3 Preliminary Results The revenue figures in this release are preliminary and unaudited, are based on information available to management as of the date of this release, and remain subject to the completion of the Company’s quarter-end financial closing procedures and review.”
Company press release, Oct 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Shareholder vote Board approved a 1-for-20 reverse stock split, effective November 12, 2026 at 4PM Local Time, with authorized common stock held at 1,500,000,000 shares and preferred stock at 300,000,000 shares. The Certificate of Amendment was filed with the Nevada Secretary of State on November 9, 2026. Form 8-K · SEC filing
Nov 10, 2026 ·
Shareholder vote Cosmos Health amended its 8-K to correct dates: a 1-for-20 reverse stock split will take effect November 13, 2026, with the Nevada Certificate of Amendment effective November 12, 2026. Authorized common stock stays at 1,500,000,000 shares. Form 8-K/A · SEC filing
Oct 22, 2026 ·
Earnings Expects Q4 2026 U.S. revenue of about $15 million and gross profit of about $10.5 million, with active U.S. subscriptions up 42% to 8,940 as of October 19, 2026 from 6,287 on October 14. Form 8-K · SEC filing · Press release
Oct 9, 2026 ·
Earnings Preliminary unaudited revenue of approximately $54.3 million for the nine months ended September 30, 2026, up 19% from $45.6 million a year earlier. Third-quarter revenue was approximately $17.4 million, and full-year 2026 revenue outlook of over $90 million was reaffirmed. Form 8-K · SEC filing · Press release
Aug 20, 2026 ·
Earnings Cosmos Health reported record Q2 2026 revenue of $18.99M, up 28.8%, and first-half revenue of $36.91M, up 29.7%. Total liabilities fell 13.3% to $40.79M and stockholders' equity rose 12.2% to $20.67M. A $5.0M share repurchase program is underway. Form 8-K · SEC filing · Press release
Aug 18, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · N/A · Upcoming Trial · A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures Registry primary completion date, not a results date
Jul 2027 · N/A · Upcoming Trial · A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
COSM holds $1.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.4M/quarter from operations,
an estimated runway of 4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:100 · High
Cash runway 4 months +40
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Nov 2025) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the date of this filing.10-Q, Aug 2026
Share count +233% in a year +20
Recent financing filings on SEC EDGAR:
Nov 7, 2025 · Shelf registration with ATM program, up to $100M · S-3
Share count 100,633,773 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full COSM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COSM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.